These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 29522713)
1. Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility. Lee JG; Ryu JH; Kim SM; Park MY; Kim SH; Shin YG; Sohn JW; Kim HH; Park ZY; Seong JY; Kim JI Biochem Pharmacol; 2018 May; 151():59-68. PubMed ID: 29522713 [TBL] [Abstract][Full Text] [Related]
2. Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant. Yap MKK; Misuan N Basic Clin Pharmacol Toxicol; 2019 May; 124(5):513-527. PubMed ID: 30417596 [TBL] [Abstract][Full Text] [Related]
3. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln. Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814 [TBL] [Abstract][Full Text] [Related]
4. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Holst JJ Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141 [TBL] [Abstract][Full Text] [Related]
5. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Malm-Erjefält M; Bjørnsdottir I; Vanggaard J; Helleberg H; Larsen U; Oosterhuis B; van Lier JJ; Zdravkovic M; Olsen AK Drug Metab Dispos; 2010 Nov; 38(11):1944-53. PubMed ID: 20709939 [TBL] [Abstract][Full Text] [Related]
6. Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. Murage EN; Gao G; Bisello A; Ahn JM J Med Chem; 2010 Sep; 53(17):6412-20. PubMed ID: 20687610 [TBL] [Abstract][Full Text] [Related]
7. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133 [TBL] [Abstract][Full Text] [Related]
8. Exendin-4(Lys Hasib A; Ng MT; Tanday N; Craig SL; Gault VA; Flatt PR; Irwin N Diabetes Metab Res Rev; 2019 Mar; 35(3):e3106. PubMed ID: 30499633 [TBL] [Abstract][Full Text] [Related]
9. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice. Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820 [TBL] [Abstract][Full Text] [Related]
11. The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. Simonsen L; Holst JJ; Madsen K; Deacon CF Regul Pept; 2013 Feb; 181():17-21. PubMed ID: 23318502 [TBL] [Abstract][Full Text] [Related]
12. α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4. Oddo A; Mortensen S; Thøgersen H; De Maria L; Hennen S; McGuire JN; Kofoed J; Linderoth L; Reedtz-Runge S Biochemistry; 2018 Jul; 57(28):4148-4154. PubMed ID: 29877701 [TBL] [Abstract][Full Text] [Related]
13. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Al-Sabah S; Donnelly D Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080 [TBL] [Abstract][Full Text] [Related]
14. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity. Ueda T; Tomita K; Notsu Y; Ito T; Fumoto M; Takakura T; Nagatome H; Takimoto A; Mihara S; Togame H; Kawamoto K; Iwasaki T; Asakura K; Oshima T; Hanasaki K; Nishimura S; Kondo H J Am Chem Soc; 2009 May; 131(17):6237-45. PubMed ID: 19361194 [TBL] [Abstract][Full Text] [Related]
15. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Furman BL Toxicon; 2012 Mar; 59(4):464-71. PubMed ID: 21194543 [TBL] [Abstract][Full Text] [Related]
16. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice. Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728 [TBL] [Abstract][Full Text] [Related]
18. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect. Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731 [TBL] [Abstract][Full Text] [Related]
19. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes. Deacon CF Peptides; 2018 Feb; 100():150-157. PubMed ID: 29412814 [TBL] [Abstract][Full Text] [Related]
20. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF; Mannucci E; Ahrén B Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]